WuXi AppTec, a drugmaker in China that manufactures multiple chemotherapies for U.S. patients, is facing scrutiny from lawmakers concerned about security threats, The New York Times reported April 15.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
